Vaxcyte, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-12-30

Reporting Person: GUGGENHIME ANDREW (President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-30	Common Stock	M	23691	$5.35	Acquired	61229	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-30	Stock Option (right to buy)	$47.95	A	42000	Acquired	2032-12-30	Common Stock (42000)	Direct
2022-12-30	Stock Option (right to buy)	$5.35	M	23691	Disposed	2030-05-11	Common Stock (23691)	Direct

Footnotes

F1: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.